Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Amyloidosis Therapeutics Market Status and Forecast (2016-2027)
  • 1.3.2 Global Amyloidosis Therapeutics Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Amyloidosis Therapeutics Supply by Company

• 2.1 Global Amyloidosis Therapeutics Sales Volume by Company
• 2.2 Global Amyloidosis Therapeutics Sales Value by Company
• 2.3 Global Amyloidosis Therapeutics Price by Company
• 2.4 Amyloidosis Therapeutics Production Location and Sales Area of Main Manufacturers
• 2.5 Trend of Concentration Rate

3 Global and Regional Amyloidosis Therapeutics Market Status by Category

• 3.1 Amyloidosis Therapeutics Category Introduction
  • 3.1.1 AG-10
  • 3.1.2 ALN-ANG
  • 3.1.3 ALN-TTRsc02
  • 3.1.4 CAEL-101
  • 3.1.5 Canakinumab
  • 3.1.6 Others
• 3.2 Global Amyloidosis Therapeutics Market by Category
  • 3.2.1 Global Amyloidosis Therapeutics Sales Volume by Category (2016-2021)
  • 3.2.2 Global Amyloidosis Therapeutics Sales Value by Category (2016-2021)
  • 3.2.3 Global Amyloidosis Therapeutics Price by Category (2016-2021)
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Amyloidosis Therapeutics Market Status by End User/Segment

• 4.1 Amyloidosis Therapeutics Segment by End User/Segment
  • 4.1.1 AL Amyloidosis
  • 4.1.2 AA Amyloidoses
  • 4.1.3 ATTR Amyloidoses
  • 4.1.4 Others
• 4.2 Global Amyloidosis Therapeutics Market by End User/Segment
  • 4.2.1 Global Amyloidosis Therapeutics Sales Volume by End User/Segment (2016-2021)
  • 4.2.2 Global Amyloidosis Therapeutics Sales Value by End User/Segment (2016-2021)
  • 4.2.3 Global Amyloidosis Therapeutics Price by End User/Segment (2016-2021)
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Amyloidosis Therapeutics Market Status by Region

• 5.1 Global Amyloidosis Therapeutics Market by Region
  • 5.1.1 Global Amyloidosis Therapeutics Sales Volume by Region
  • 5.1.2 Global Amyloidosis Therapeutics Sales Value by Region
• 5.2 North America Amyloidosis Therapeutics Market Status
• 5.3 Europe Amyloidosis Therapeutics Market Status
• 5.4 Asia Pacific Amyloidosis Therapeutics Market Status
• 5.5 Central & South America Amyloidosis Therapeutics Market Status
• 5.6 Middle East & Africa Amyloidosis Therapeutics Market Status

6 North America Amyloidosis Therapeutics Market Status

• 6.1 North America Amyloidosis Therapeutics Market by Country
  • 6.1.1 North America Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
  • 6.1.2 North America Amyloidosis Therapeutics Sales Value by Country (2016-2021)
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Amyloidosis Therapeutics Market Status

• 7.1 Europe Amyloidosis Therapeutics Market by Country
  • 7.1.1 Europe Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
  • 7.1.2 Europe Amyloidosis Therapeutics Sales Value by Country (2016-2021)
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Amyloidosis Therapeutics Market Status

• 8.1 Asia Pacific Amyloidosis Therapeutics Market by Country
  • 8.1.1 Asia Pacific Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
  • 8.1.2 Asia Pacific Amyloidosis Therapeutics Sales Value by Country (2016-2021)
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Amyloidosis Therapeutics Market Status

• 9.1 Central & South America Amyloidosis Therapeutics Market by Country
  • 9.1.1 Central & South America Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
  • 9.1.2 Central & South America Amyloidosis Therapeutics Sales Value by Country (2016-2021)
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Amyloidosis Therapeutics Market Status

• 10.1 Middle East & Africa Amyloidosis Therapeutics Market by Country
  • 10.1.1 Middle East & Africa Amyloidosis Therapeutics Sales Volume by Country (2016-2021)
  • 10.1.2 Middle East & Africa Amyloidosis Therapeutics Sales Value by Country (2016-2021)
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Supply Chain and Manufacturing Cost Analysis

• 11.1 Supply Chain Analysis
• 11.2 Production Process Chart Analysis
• 11.3 Raw Materials and Key Suppliers Analysis
  • 11.3.1 Raw Materials Introduction
  • 11.3.2 Raw Materials Key Suppliers List
• 11.4 Amyloidosis Therapeutics Manufacturing Cost Analysis
• 11.5 Amyloidosis Therapeutics Sales Channel and Distributors Analysis
  • 11.5.1 Amyloidosis Therapeutics Sales Channel
  • 11.5.2 Amyloidosis Therapeutics Distributors
• 11.6 Amyloidosis Therapeutics Downstream Major Buyers

12 Global Amyloidosis Therapeutics Market Forecast by Category and by End User/Segment

• 12.1 Global Amyloidosis Therapeutics Sales Volume and Sales Value Forecast (2022-2027)
• 12.2 Global Amyloidosis Therapeutics Forecast by Category
  • 12.2.1 Global Amyloidosis Therapeutics Sales Volume Forecast by Category
  • 12.2.2 Global Amyloidosis Therapeutics Sales Value Forecast by Category
  • 12.2.3 Global Amyloidosis Therapeutics Price Forecast by Category
• 12.3 Global Amyloidosis Therapeutics Forecast by End User/Segment
  • 12.3.1 Global Amyloidosis Therapeutics Sales Volume Forecast by End User/Segment
  • 12.3.2 Global Amyloidosis Therapeutics Sales Value Forecast by End User/Segment
  • 12.3.3 Global Amyloidosis Therapeutics Price Forecast by End User/Segment

13 Global Amyloidosis Therapeutics Market Forecast by Region/Country

• 13.1 Global Amyloidosis Therapeutics Market Forecast by Region (2022-2027)
  • 13.1.1 Global Amyloidosis Therapeutics Sales Volume Forecast by Region (2022-2027)
  • 13.1.2 Global Amyloidosis Therapeutics Sales Value Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 SOM Innovation Biotech SL
  • 14.1.1 Company Information
  • 14.1.2 Amyloidosis Therapeutics Product Introduction
  • 14.1.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Prothena Corporation Plc
  • 14.2.1 Company Information
  • 14.2.2 Amyloidosis Therapeutics Product Introduction
  • 14.2.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 ProteoTech, Inc.
  • 14.3.1 Company Information
  • 14.3.2 Amyloidosis Therapeutics Product Introduction
  • 14.3.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Pfizer Inc.
  • 14.4.1 Company Information
  • 14.4.2 Amyloidosis Therapeutics Product Introduction
  • 14.4.3 Pfizer Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Onyx Pharmaceuticals, Inc.
  • 14.5.1 Company Information
  • 14.5.2 Amyloidosis Therapeutics Product Introduction
  • 14.5.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Millennium Pharmaceuticals, Inc.
  • 14.6.1 Company Information
  • 14.6.2 Amyloidosis Therapeutics Product Introduction
  • 14.6.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Isis Pharmaceuticals, Inc.
  • 14.7.1 Company Information
  • 14.7.2 Amyloidosis Therapeutics Product Introduction
  • 14.7.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 GlaxoSmithKline Plc
  • 14.8.1 Company Information
  • 14.8.2 Amyloidosis Therapeutics Product Introduction
  • 14.8.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Celgene Corporation
  • 14.9.1 Company Information
  • 14.9.2 Amyloidosis Therapeutics Product Introduction
  • 14.9.3 Celgene Corporation Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Bsim2
  • 14.10.1 Company Information
  • 14.10.2 Amyloidosis Therapeutics Product Introduction
  • 14.10.3 Bsim2 Amyloidosis Therapeutics Sales Volume, Price, Sales Value and Gross Margin (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Bellus Health Inc.
• 14.12 Arcturus Therapeutics, Inc
• 14.13 Alnylam Pharmaceuticals, Inc.

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Amyloidosis Therapeutics market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Amyloidosis Therapeutics market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
AG-10
ALN-ANG
ALN-TTRsc02
CAEL-101
Canakinumab
Others

Segmented by End User/Segment
AL Amyloidosis
AA Amyloidoses
ATTR Amyloidoses
Others

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
SOM Innovation Biotech SL
Prothena Corporation Plc
ProteoTech, Inc.
Pfizer Inc.
Onyx Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Celgene Corporation
Bsim2
Bellus Health Inc.
Arcturus Therapeutics, Inc
Alnylam Pharmaceuticals, Inc.